INS and colorectal carcinoma: Moreover, the use of metformin was associated with a reduced CRC risk (odd ratio, OR 0.47, 95% and confidence interval, CI 0.24–0.92) risk as compared to increased CRC risk by insulin (OR 2.20, 95% CI 1.12–4.33) [76].